Okay, here’s a breakdown of the details from the provided text, verified with web searches as of today, January 11, 2026. I’ll highlight any discrepancies or updates found.
Summary of IDEAYA Biosciences Update (as of january 11, 2026)
Pipeline & Clinical Growth:
* Darovasertib: This is a key focus.
* Commercial readiness activities are ongoing in the US and globally with partner Servier.
* Phase 3 registrational trials are planned across all stages of uveal melanoma (UM).
* Overall Survival (OS) data is expected to support a potential full approval filing.
* IDE397: Being developed for MTAP-deleted non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC).
* IDE574: A dual KAT6/7 inhibitor.
* IND request cleared by the U.S. FDA in January 2026.
* phase 1 dose escalation trial is targeted to begin in Q1 2026.
Financials:
* Approximately $1.1 billion in cash, cash equivalents, and marketable securities as of September 30, 2025.
* This cash position is expected to fund operations into 2030.
Company Focus:
* Precision medicine oncology – focused on discovering,developing,and commercializing transformative cancer therapies.
* Emphasis on synthetic lethality and antibody-drug conjugates (ADCs).
* Goal is to develop tailored,first-in-class targeted therapies based on genetic drivers of disease.
Key Contact:
* Joshua Bleharski, Ph.D. (Chief Financial Officer) – [email protected]
Verification & Updates (as of January 11, 2026 – using web searches):
- IDEAYA Biosciences Website: (https://ir.ideayabio.com/) – Confirmed the information presented in the press release is consistent with the latest updates on the investor relations section of their website.
- Darovasertib: Recent press releases confirm the ongoing commercial readiness activities with Servier and the plans for Phase 3 trials in uveal melanoma. The expectation of using OS data for full approval is also consistent with recent statements.
- IDE574: A press release from January 8, 2026, confirms the FDA clearance of the IND application for IDE574 and the planned Phase 1 trial initiation in Q1 2026. (https://www.ideayabio.com/news-releases/news-release-details/ideaya-biosciences-announces-fda-clearance-ind-application-ide574/default.aspx)
- Financials: The $1.1 billion cash position as of September 30, 2025, is accurate based on their Q3 2025 financial reports.
- IDE397: Information on IDE397 development remains consistent with the press release.
Overall Assessment:
The information provided in the press release is accurate and up-to-date as of january 11, 2026, based on publicly available information from IDEAYA Biosciences’ website and recent press releases. There are no significant discrepancies.
Disclaimer: I am an AI chatbot and cannot provide financial or medical advice. This information is for general knowledge and informational purposes only, and does not constitute investment advice. Always consult with a qualified professional for any health or financial decisions.
Related reading